This article documents both the published trial structure and the community-reported cycle patterns. The two are different in length, dose, and intent — and both are reported here, not recommended.
Research-context information only. Retatrutide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Two Cycle Models — Published vs Community-Reported
The published Phase 2 design and the self-reported community pattern are not the same protocol.
| Parameter | Phase 2 trial protocol | Self-reported community protocol |
|---|---|---|
| Cycle structure | Continuous; no scheduled breaks | 8 weeks on / 8 weeks off (most cited) |
| Cycle length | 48 weeks (trial duration) | 8 weeks per on-cycle |
| Titration cadence | Every 4 weeks (2 → 4 → 8 → 12 mg) | Every 2-4 weeks based on tolerance |
| Peak weekly dose | 12 mg | Typically 1.5-4 mg |
| Injection frequency | Once weekly | Often split 2-3x/week |
| Maintenance phase | Not part of Phase 2 design | Some community sources self-report stepping down to 2x/week dosing |
| Source | Jastreboff 2023, NEJM | Forum-reported / self-reported community sources |
Community protocols are conservative relative to the trial — both in peak weekly mg and in adding cycle breaks the trial did not include. For the underlying dosing math and titration logic, see the Retatrutide Dosing Guide.
Standard Community Cycle Structure
Self-reported community protocols most commonly describe an 8-on / 8-off structure: 8 weeks dosing, then an 8-week off window. The most cited reasoning is appetite-tone recovery and minimization of receptor downregulation, though direct trial evidence for either claim is limited.
A common community-reported on-cycle profile:
| Week | Self-reported weekly dose | Common split |
|---|---|---|
| 1 | 0.25 mg | Single dose, AM, empty stomach |
| 2 | 0.5 mg | Single dose or split 0.25 × 2 |
| 3 | 0.5-1 mg | Often split 0.5 × 2 |
| 4 | 1-1.5 mg | Commonly 0.5 × 3 |
| 5 | 1.5-2 mg | Commonly 0.5-1 mg × 2-3 |
| 6 | 2-3 mg | Commonly 1 mg × 2-3 |
| 7 | 2-4 mg | Steady-state dose for most users |
| 8 | 2-4 mg | Steady-state, then transition to off-cycle or taper |
Phase 2 trial titration moved faster: 2 mg/week for weeks 1-4, 4 mg/week for weeks 5-8, 8 mg/week for weeks 9-12, then 12 mg/week from week 13 onward. Self-reported community protocols slow this titration substantially — most users self-report holding well below the trial ceiling for tolerability reasons.
Tapering Off Retatrutide
Community-reported taper protocols commonly step the weekly dose down by approximately 50% every 2 weeks before fully discontinuing. The intent reported is to soften appetite rebound and reduce the abruptness of GLP-1 receptor withdrawal.
A representative community-reported taper from a 2 mg/week ceiling:
| Week | Self-reported weekly dose |
|---|---|
| Taper week 1-2 | 1 mg/week |
| Taper week 3-4 | 0.5 mg/week |
| Taper week 5-6 | 0.25 mg/week |
| Taper week 7+ | Off |
Trial subjects in Phase 2 did not taper — the trial extension was open-label continuation, not a structured taper. Tapering is a community-reported behavior. Direct trial data comparing taper vs cold-stop discontinuation has not been published for retatrutide.
What Community Sources Report About the Off-Cycle
The off-cycle is where the rebound risk is most discussed in self-reported community sources. Three patterns recur:
- Appetite returns within 1-3 weeks of stopping. GLP-1-class receptor effects on satiety wane rapidly without continued dosing. Self-reported users commonly describe this as the most pronounced off-cycle change.
- Weight regain pattern varies with maintenance behavior. Community sources who self-report continued caloric discipline and resistance training during the off-cycle describe smaller regains than those who don't. Direct trial data: the STEP 1 extension reported approximately two-thirds of weight loss regained within one year after stopping semaglutide (Wilding 2022, Diabetes Obes Metab). Retatrutide-specific discontinuation data is not yet published.
- Sleep, mood, and energy reports. Self-reported community sources describe normalization of meal frequency, reduced gastric-emptying delay, and reduced injection-site fatigue during the off-cycle.
Community-reported maintenance-during-off-cycle behaviors include cardiovascular training, resistance training, and high-protein dietary patterns. None of these are validated trial protocols for retatrutide specifically — they are reported community behaviors associated with reduced regain.
Restart Protocols After an Off-Cycle
Self-reported community restart protocols generally describe re-titrating from a lower starting dose rather than resuming the prior on-cycle ceiling. The common pattern:
| Week | Self-reported restart dose |
|---|---|
| Week 1 | 0.25 mg (re-introduction) |
| Week 2-3 | 0.5 mg |
| Week 4-5 | 1 mg |
| Week 6-8 | Step toward prior on-cycle ceiling (e.g., 2 mg/week) |
The reasoning reported by community sources for re-titrating: GI tolerance can reset during the off-cycle, and jumping back to a 2-4 mg ceiling without re-titration tends to reproduce week-1 nausea. Trial data on retatrutide restart protocols has not been published; self-reported users describe re-titration on the same timeline as initial titration, just compressed.
How Long Community Sources Report Staying On
There is no single community-reported cycle ceiling. Two patterns recur:
- Cyclical (8-on / 8-off, repeating). The dominant self-reported pattern. Users describe running 2-3 cycles toward a target weight, then a longer off-window or maintenance phase.
- Goal-driven continuous. Less commonly self-reported. Users describe continuous dosing across 16-32 weeks until a target weight, then transition to a maintenance dose or off-cycle. This pattern is closer to the Phase 2 trial design (continuous across 48 weeks) than the 8-on / 8-off cyclical pattern.
Phase 2 trial subjects ran continuous dosing across 48 weeks; published 48-week data did not document a plateau on the 12 mg arm that justified a cycle break (Jastreboff 2023, NEJM). Self-reported community cycling is a more conservative pattern than the trial supported, driven by community-level concerns about receptor downregulation and long-term tolerability that the 48-week trial window did not directly address.
For per-cycle vial math and budget estimation, see the Retatrutide Cost & Vial Math page.
